This study is a phase 1/2 trial of Tinostamustine conditioning and autologous stem cell transplantation for treatment in relapsed / refractory multiple myeloma. The main purpose of this study is to assess the safety and tolerability of Tinostamustine as conditioning in the phase 1 part of the study and the safety, tolerability and efficacy of Tinostamustine in phase 2.
This study evaluates the efficacy, safety and pharmacokinetics of EDO-S101 in patients with relapsed/refractory hematologic malignancies. All patients will receive EDO-S101.
Mundipharma EDO GmbH
Create your account today and get matched to myeloma treatments and trials around the US.
Weekdays 9am - 5pm EST